Published August 14, 2021 | Version Published article
Journal article Open

Octacalcium phosphate: Innovative vehicle for the local biologically active substance delivery in bone regeneration

  • 1. Rudolfs Cimdins Riga Biomaterials Innovation and Development Centre, Institute of General Chemical Engineering, Faculty of Materials Science and Applied Chemistry, Riga Technical University, Pulka 3, Riga, LV-1007, Latvia
  • 2. Rudolfs Cimdins Riga Biomaterials Innovation and Development Centre, Institute of General Chemical Engineering, Faculty of Materials Science and Applied Chemistry, Riga Technical University, Pulka 3, Riga, LV-1007, Latvia; Baltic Biomaterials Centre of Excellence, Headquarters at Riga Technical University, Riga, Latvia

Description

Disadvantages of conventional drug delivery systems (DDS), such as systemic circulation, interaction with physiochemical factors, reduced bioavailability, and insufficient drug concentration at bone defect site, have underlined the importance of developing efficacious local drug delivery systems. Octacalcium phosphate (OCP) is presumed to be the precursor of biologically formed apatite, owing to its similarity to hydroxyapatite (HAp) and readiness to convert to it. Specific crystal structure of OCP is constructed of compiled apatite layers and water layers, which make possible the incorporation of various ions in its structure, making it feasible to alter the overall effect OCP has in the system. Next to that intrinsic property, characteristics as high solubility, biodegradability and osteoconductivity have made it indispensable to tailor OCP as a carrier material. In this review, we present the main characteristics and progress done on utilizing OCP as an innovative vehicle and provide suggestions for possible research pathways and advantages for local drug delivery in bone tissue engineering.

Notes

Premurosa BBCE Baltic Biomaterials Centre of Excellence

Files

1-s2.0-S174270612100547X-main.pdf

Files (4.8 MB)

Name Size Download all
md5:6ace20f45aee8711643a5bf99da4a5df
4.8 MB Preview Download

Additional details

Related works

Funding

PREMUROSA – Precision medicine for muscoloskeletal regeneration, prosthetics and active ageing 860462
European Commission
BBCE – Baltic Biomaterials Centre of Excellence 857287
European Commission